Responses
Oral Plenary
Plenary V
IGCS20_1271
14 Phase II trial evaluating efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.